Duvelisib was the 2nd PI3K inhibitor authorised because of the FDA, also based on a phase III randomized trial.130 The efficacy and safety profile with the drug appear equivalent with All those of idelalisib, Otherwise marginally advantageous. Relating to option BTK inhibitors, there are plenty of merchandise in enhancement, but only acalabrutinib